

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/763,190
Filing Date	January 26, 2004
First Named Inventor	Pnina FISHMAN et al
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	FISHMAN=9B

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AX	US 2002/115685 A1	08-22-2002	Pnina FISHMAN et al	page 1, paragraph 13, page 3, paragraph 15; figures, examples
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

Zach Howard

Date  
Considered

3/22/05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/763,190
		Filing Date	January 26, 2004
		First Named Inventor	FISHMAN, Pnina
		Group Art Unit	1645
		Examiner Name	
Sheet 2	2	Attorney Docket Number	FISHMAN=9B

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
3H	AB	BAHARAV et al "The Effect of Adenosine and the A3 Adenosine Receptor Agonist IB-Meca on Joint Inflammation and Autoimmune Diseases Models" <u>International Journal of Molecular Medicine</u> , 10(1):S104 (2002)	
3H	AC	BAR-YEHUDA et al "Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: A new class of myeloprotective agents" <u>International Journal of Molecular Medicine</u> , 10(1):S100 (2002)	
3H	AD	BONVIN et al "Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells" <u>Biochim.Biophys.Acta.</u> , 1495:308-318 (2000)	
3H	AE	FANG et al "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A." <u>Proc.Natl.Acad.Sci.</u> 97:11960-11965 (2000)	
3H	AF	FERKEY et al "GSK-3: New Thoughts on an Old Enzyme" <u>Dev.Biol.</u> , 225:471-479 (2000)	
	AG	<del>FISHMAN et al "The A3 adenosine receptor: A new target for cancer therapy and chemoprotection" <u>International Journal of Molecular Medicine</u>, 6(1):S60 (2000)</del>	
3H	AH	FISHMAN et al "Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 Adenosine Receptors" <u>Journal of Cellular Physiology</u> , 183(3):393-398 (2000)	
3H	AI	FISHMAN et al "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells" <u>Oncogene</u> , 21(25):4060-4064 (2002)	
3H	AJ	HASKÓ et al "Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice." <u>Journal of Immunology</u> , 157(10): 4634-4640 (1996)	
3H	AK	MADI et al "High Expression of A3ARS in Melanoma and Colon Carcinoma Cel Lines: A Target for Tumor Cell Growth Inhibition" <u>Drug Development Research</u> , 56(4):560 (2002)	
3H	AL	OLAH et al "The role of receptor structure in determining adenosine receptor activity" <u>Pharmacol.Ther.</u> , 85:55-75 (2000)	
3H	AM	POULSON et al "Adenosine receptors: new opportunities for future drugs." <u>Bioorg.Med.Chem.</u> , 6:619-641 (1998)	

Examiner Signature	<i>Zach Howard</i>	Date Considered	3-22-05
--------------------	--------------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.